Mona Khattab
Research Subjects
Mona Khattab has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Dennis Henzler
Institute of Management for Medicine and Health Sciences, University of Bayreuth, Bayreuth, Germany
1 shared publication - Derk Ludolf Willems
Department of Ethics, Law & Humanities, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
1 shared publication - Eckhard Nagel1 shared publication
- Georg Ludwig Lindinger1 shared publication
- Hanno L. Tan
Department of Experimental Cardiology, Amsterdam University Medical Centre, University of Amsterdam
1 shared publication - Marieke A. R. Bak
Department of Ethics, Law and Humanities Amsterdam UMC Amsterdam The Netherlands
1 shared publication
Latest Publications
- Open Access
- 25 August 2026
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 28, e96968
Patients’ Perspectives on Applications of AI and Personalized Medicine in Life-Threatening Heart Disease: European Cross-Sectional Patient Questionnaire Study
Background: The growing integration of personalized risk prediction (PRP) and AI substantially reshapes diagnostic and therapeutic decision-making in health care. At the same time, its responsible adoption depends not only on technical performance, but also on patients’ perspectives and acceptance. Objective: This study systematically examined patients’ perspectives across several European countries and explored how patients’ technology-related attitudes relate to their evaluations of personalized and AI-supported approaches in cardiac care. As part of the PROFID (Prevention of Sudden Cardiac Death After Myocardial Infarction by Defibrillator Implantation) project, its focus is on the ethical use of PRP and AI in the clinical context of decision-making regarding sudden cardiac death (SCD) prevention and implantable cardioverter-defibrillator (ICD) implantation. Methods: The study used a cross-sectional survey design with a standardized questionnaire including multimedia content. The target population comprised adults aged 18 years or older living in 6 European countries who met at least one of the following (self-reported) clinical criteria: heart failure, myocardial infarction (MI), cardiac arrest, or current ICD implantation. An exploratory factor analysis (EFA) was used to identify and evaluate internally consistent factors, and subsequent regression analyses examined associations between these factors and technological openness, sociodemographic characteristics, and patients’ views on PRP and AI in cardiac care. Results: The sample consisted of 470 participants from Germany (n=210), the Netherlands (n=86), the United Kingdom (n=145), and 3 other European countries (n=29; Austria, Belgium, and Spain). Overall, 51.9% (244/470) of respondents were male and 48.1% (226/470) were female. The mean age of the sample was 61.12 (SD 12.62) years. The EFA showed six clearly interpretable factors: (1) perceived benefits and support of PRP models in medical decision-making (MDM), (2) perceived benefits and support of AI in MDM, (3) transparency expectations in algorithmic decision-making, (4) support for delegating decisions to algorithms, (5) self-reported AI literacy, and (6) preference for shared decision-making (SDM). The regression analysis showed the relations of technological readiness, self-reported AI literacy, support for delegation of decisions to algorithms, transparency expectations in algorithmic decision-making, preferences for SDM, educational attainment, gender, and age to find associations with patients’ perceived benefits and support of PRP or AI in MDM. Conclusions: The findings support existing assumptions while also highlighting additional aspects that should be considered if high-level technologies are used in decision-making processes related to ICD implantation. PRP and AI were generally perceived as useful tools to support decision-making regarding ICD indication, provided transparency is ensured and patients remain actively involved in the decision-making process. Mandatory use and full delegation to decision-making directly by AI were broadly rejected. The attributed acceptance of delegation to PRP models was significantly higher than AI. In summary, implementation should support empathetic communication, patient involvement, and individual and institutional responsibility.
- 25 August 2026
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 28, e96968
Open AccessPatients’ Perspectives on Applications of AI and Personalized Medicine in Life-Threatening Heart Disease: European Cross-Sectional Patient Questionnaire Study
Background: The growing integration of personalized risk prediction (PRP) and AI substantially reshapes diagnostic and therapeutic decision-making in health care. At the same time, its responsible adoption depends not only on technical performance, but also on patients’ perspectives and acceptance. Objective: This study systematically examined patients’ perspectives across several European countries and explored how patients’ technology-related attitudes relate to their evaluations of personalized and AI-supported approaches in cardiac care. As part of the PROFID (Prevention of Sudden Cardiac Death After Myocardial Infarction by Defibrillator Implantation) project, its focus is on the ethical use of PRP and AI in the clinical context of decision-making regarding sudden cardiac death (SCD) prevention and implantable cardioverter-defibrillator (ICD) implantation. Methods: The study used a cross-sectional survey design with a standardized questionnaire including multimedia content. The target population comprised adults aged 18 years or older living in 6 European countries who met at least one of the following (self-reported) clinical criteria: heart failure, myocardial infarction (MI), cardiac arrest, or current ICD implantation. An exploratory factor analysis (EFA) was used to identify and evaluate internally consistent factors, and subsequent regression analyses examined associations between these factors and technological openness, sociodemographic characteristics, and patients’ views on PRP and AI in cardiac care. Results: The sample consisted of 470 participants from Germany (n=210), the Netherlands (n=86), the United Kingdom (n=145), and 3 other European countries (n=29; Austria, Belgium, and Spain). Overall, 51.9% (244/470) of respondents were male and 48.1% (226/470) were female. The mean age of the sample was 61.12 (SD 12.62) years. The EFA showed six clearly interpretable factors: (1) perceived benefits and support of PRP models in medical decision-making (MDM), (2) perceived benefits and support of AI in MDM, (3) transparency expectations in algorithmic decision-making, (4) support for delegating decisions to algorithms, (5) self-reported AI literacy, and (6) preference for shared decision-making (SDM). The regression analysis showed the relations of technological readiness, self-reported AI literacy, support for delegation of decisions to algorithms, transparency expectations in algorithmic decision-making, preferences for SDM, educational attainment, gender, and age to find associations with patients’ perceived benefits and support of PRP or AI in MDM. Conclusions: The findings support existing assumptions while also highlighting additional aspects that should be considered if high-level technologies are used in decision-making processes related to ICD implantation. PRP and AI were generally perceived as useful tools to support decision-making regarding ICD indication, provided transparency is ensured and patients remain actively involved in the decision-making process. Mandatory use and full delegation to decision-making directly by AI were broadly rejected. The attributed acceptance of delegation to PRP models was significantly higher than AI. In summary, implementation should support empathetic communication, patient involvement, and individual and institutional responsibility.